During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade Also check out my Top 2011 Stock Gainers, Stocks to Buy 2011.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow -0.97% to 11398. S&P -1.02% to 1204. Nasdaq +0.12% to 2309.
Treasurys: 30-year +1.25%. 10-yr +0.59%. 5-yr -0.819%.
Commodities: Crude -2.55% to $85.93. Gold -1.81% to $1779.65.
Currencies: Euro -0.82% vs. dollar. Yen -0.33%. Pound +0.55%.
After Hours Earning News:
Microcap Kona Grill (KONA) jumps after raising its Q3 revenue and net income guidance due to strong sales growth. The updated guidance anticipates same-store sales growth of approximately 9% Y/Y, compared to 6% growth previously forecasted. Shares +16% AH.
Western Gas Partners (WES) announces a 5M unit secondary offering. Shares -4.3% AH.
Netflix's (NFLX -7.4%) thus far questionable decision to raise prices and now its move to split the company into 2 segments by hilariously imagining the movie rental leader as a sandwich shop.
Newcastle Investment (NCT) announces a 22.5M share secondary offering. Citigroup, Barclays Capital, Morgan Stanley and UBS are acting as joint book runners, with Macquarie and Stifel Nicolaus Weisel acting as co-managers. Shares -9.7% AH.
Western Gas Partners (WES) announces a 5M unit secondary offering. Shares -4.3% AH.
Netflix's (NFLX -7.4%) thus far questionable decision to raise prices and now its move to split the company into 2 segments by hilariously imagining the movie rental leader as a sandwich shop.
Newcastle Investment (NCT) announces a 22.5M share secondary offering. Citigroup, Barclays Capital, Morgan Stanley and UBS are acting as joint book runners, with Macquarie and Stifel Nicolaus Weisel acting as co-managers. Shares -9.7% AH.
Jazz Pharmaceuticals (JAZZ) is now down 5.1% AH following the announcement of its merger with Azur Pharma.
Gilead Sciences (GILD) says the HIV Phase 3 clinical trial of its potential blockbuster “Quad” regimen used for the treatment of HIV-1 met its primary endpoint.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
